Engineered anti-CD19 monoclonal antibodies (CD19 mAbs) with enhanced cytolytic activity are commonly used as B cell-depleting therapies for treating R/R cases of different B-cell lymphomas as well as autoimmune diseases [10,11]. The gene discussed is CD19; the disease is autoimmune disease.